Mauricio Moel
Analyses trial and real-world data on repurposed longevity drugs at AgelessRx and led the reporting of the PEARL rapamycin trial
Co-Founder, AgelessRx · Researcher, Division of Research and Applied Sciences, AgelessRx · Research in computational microbial ecology, Department of Biology, Boston University · BA in Neurobiology, Boston University
AgelessRx (Ann Arbor, Michigan, USA) ↗
Moel is the first author of MOE2025, the PEARL trial report, and one of the three people the paper credits with the data analysis. That analysis is what makes the paper worth reading: the pre-registered primary endpoint, visceral fat on a DXA scan, moved essentially not at all (p = 0.942), and the report says so plainly instead of promoting a secondary finding into the headline.
The secondary results he analysed are narrower than the press coverage suggested. Among women taking 10 mg of rapamycin weekly, lean tissue mass and self-reported pain improved; participants on 5 mg reported better emotional well-being and general health; blood biomarkers stayed inside normal ranges and adverse events were similar in all three groups. With 114 people finishing 48 weeks, these are signals worth chasing in a properly powered follow-up, not evidence that the drug works.
Before he moved into longevity medicine he was at Boston University, where he took a BA in neurobiology and co-authored a computational study with Daniel Segre's group on 'costless' metabolites - compounds a bacterium can release without paying any growth penalty, which helps explain how stable cross-feeding between species can arise at all. At AgelessRx he has stayed on the data side, also co-authoring the company's work on how much rapamycin actually reaches the blood from compounded versus commercial formulations.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2025 | H | Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results MOE2025 First author; the paper's author contributions list him as one of the three people who performed the data analysis for the PEARL trial. |
Co-authors in the Atlas
People with a profile here who share at least one study with Mauricio Moel.
- Girish Harinath Designs, analyses and writes up human studies of repurposed drugs such as rapamycin at a longevity telehealth company, turning trial and real-world prescription data into peer-reviewed evidence
- Sajad Zalzala Family physician who co-founded AgelessRx and, as senior author, co-led PEARL, a year-long randomised trial of low-dose intermittent rapamycin in healthy older adults